Comparison of Arkray/ELITech ADAMS HA‐8180V® with Bio‐Rad Variant,<sup>TM</sup>II Turbo2.0® and Tosoh Bioscience HLC®‐723G8 for HbA1c Determination

Badiou, Stéphanie; Guillot, J.M.; Kuster, Nils; Bargnoux, Anne-Sophie; Aguilar-Martinez, Patricia; Boissier, Elodie; Cristol, Jean‐Paul; Dupuy, Anne‐Marie

doi:10.1002/jcla.21705

Cited by 9 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During our study, we used an earlier software version 5.23 on TOSOH G8. Previous studies demonstrated reliable HbS, HbC, and HbD identification using TOSOH G8 in variant HbA1c mode . However, these studies focused only on effective detection of Hb variants and not on Hb variant quantification.…”

Section: Discussionmentioning

confidence: 99%

Hemoglobin S monitoring on TOSOH G8 in hemoglobin A1c mode in case of urgent red blood cell exchange

Aelst

Nackers

Desmet³

et al. 2018

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Hemoglobin S monitoring on TOSOH G8 in hemoglobin A1c mode in case of urgent red blood cell exchange

Aelst

Nackers

Desmet³

et al. 2018

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…HBB increases the risk of having T2D ( 39 ). HBD is detected in various systematic tests for diabetes ( 40 ). HBG2 is upregulated in diabetic retinopathy ( 41 ).…”

Section: Discussionmentioning

confidence: 99%

Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes

Zhang

2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundType 2 diabetes (T2D) is a common chronic disease with many serious complications. Celastrol can prevent and treat type 2 diabetes by reversing insulin resistance in a number of ways. However, the specific mechanisms by which celastrol prevents and treats T2D are not well understood. The aim of this study was to explore the key gene targets and potential signaling pathway mechanisms of celastrol for the treatment of T2D.MethodsGSE184050 was downloaded from the Gene Expression Omnibus online database. Blood samples from patients and healthy individuals with T2D were analyzed to identify differentially expressed genes (DEGs), and a protein−protein interaction network (PPI) was constructed. Key gene analysis of DEGs was performed using the MCODE plugin in Cystoscope as well as the Hubba plugin, and intersections were taken to obtain hub genes, which were displayed using a Venn diagram. Enrichment analysis was then performed via the ClueGo plugin in Cytoscape and validated using Gene Set Enrichment Analysis. The therapeutic targets of celastrol were then analyzed by pharmacophore network pharmacology, intersected to identify the therapeutic targets of celastrol, enriched for all targets, and intersected to obtain the signaling pathways for celastrol treatment. The protein structures of the therapeutic targets were predicted using the artificial intelligence AlphaFold2. Finally, molecular docking was used to verify whether celastrol could be successfully docked to the predicted targets.Results618 DEGs were obtained, and 9 hub genes for T2D were identified by the MCODE and Hubba plug-ins, including ADAMTS15, ADAMTS7, ADAMTSL1, SEMA5B, ADAMTS8, THBS2, HBB, HBD and HBG2. The DEG-enriched signaling pathways mainly included the ferroptosis and TGF-beta signaling pathways. A total of 228 target genes were annotated by pharmacophore target analysis, and the therapeutic targets were identified, including S100A11, RBP3, HBB, BMP7 and IQUB, and 9 therapeutic signaling pathways were obtained by an intersectional set. The protein structures of the therapeutic targets were successfully predicted by AlphaFold2, and docking was validated using molecular docking.ConclusionCelastrol may prevent and treat T2D through key target genes, such as HBB, as well as signaling pathways, such as the TGF-beta signaling pathway and type II diabetes mellitus.

show abstract

“…So, in our HPLC method, Hb Hope and HbA1c elute in the same window leading to probable overestimation, like in other studies. 5,6 It is possible that alpha-thalassemia in patient-B justifies the lower overestimation of HbA1c in relation to patient-A in D-10 (Table 1).…”

Section: Letter To the Editormentioning

confidence: 99%

Interference of Hemoglobin (Hb) Hope on Measurement of HbA1c Using an HPLC Method

Lorenzo-Medina,

De-La-Iglesia,

Ropero

et al. 2021

J Diabetes Sci Technol

View full text Add to dashboard Cite

Comparison of Arkray/ELITech ADAMS HA‐8180V® with Bio‐Rad Variant,^TMII Turbo2.0® and Tosoh Bioscience HLC®‐723G8 for HbA1c Determination

Cited by 9 publications

References 20 publications

Hemoglobin S monitoring on TOSOH G8 in hemoglobin A1c mode in case of urgent red blood cell exchange

Hemoglobin S monitoring on TOSOH G8 in hemoglobin A1c mode in case of urgent red blood cell exchange

Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes

Interference of Hemoglobin (Hb) Hope on Measurement of HbA1c Using an HPLC Method

Contact Info

Product

Resources

About

Comparison of Arkray/ELITech ADAMS HA‐8180V® with Bio‐Rad Variant,TMII Turbo2.0® and Tosoh Bioscience HLC®‐723G8 for HbA1c Determination

Cited by 9 publications

References 20 publications

Hemoglobin S monitoring on TOSOH G8 in hemoglobin A1c mode in case of urgent red blood cell exchange

Hemoglobin S monitoring on TOSOH G8 in hemoglobin A1c mode in case of urgent red blood cell exchange

Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes

Interference of Hemoglobin (Hb) Hope on Measurement of HbA1c Using an HPLC Method

Contact Info

Product

Resources

About

Comparison of Arkray/ELITech ADAMS HA‐8180V® with Bio‐Rad Variant,^TMII Turbo2.0® and Tosoh Bioscience HLC®‐723G8 for HbA1c Determination